Blockade of epidermal growth factor receptor (EGFR) activity

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 3, 2005, Pages 179-192

  Jimeno, Antonio ^a,b,c,d   Hidalgo, Manuel ^a,d,e,f,g,h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NAVARRA   (Spain)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

EGFR; Targeted therapies

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACNE; ASTHENIA; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ESOPHAGUS CANCER; FEVER; FOLLICULITIS; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; KIDNEY CANCER; KIDNEY METASTASIS; LIVER DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR REGRESSION; VASCULITIS; VOMITING;

EID: 13844255763     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.10.005     Document Type: Review

References (122)

1. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics, 2003 CA Cancer J Clin 53 1 2003 5 26
2. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
3. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 12 2003 2237 2246
4. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial J Am Med Assoc 290 16 2003 2149 2158
5. Shepherd F, Pereira J, Ciuleanu T, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004. J Clin Oncol 22, 14S (July 15 Suppl) (abstr 7022).
6. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
7. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
8. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 5 2003 427 434
9. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003;3(2):85-8.
10. A. Wells EGF receptor Int J Biochem Cell Biol 31 6 1999 637 643
11. C.L. Arteaga The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 18 Suppl 2001 32S 40S
12. R. Pinkas-Kramarski, L. Soussan, and H. Waterman Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 10 1996 2452 2467
13. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2 2001 127 137
14. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 7 1997 1647 1655
15. R. Worthylake, L.K. Opresko, and H.S. Wiley ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J Biol Chem 274 13 1999 8865 8874
16. J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 103 2 2000 211 225
17. J. Blenis Signal transduction via the MAP kinases: proceed at your own RSK Proc Natl Acad Sci USA 90 13 1993 5889 5892
18. B.M. Burgering, and P.J. Coffer Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction Nature 376 6541 1995 599 602
19. T.S. Lewis, P.S. Shapiro, and N.G. Ahn Signal transduction through MAP kinase cascades Adv Cancer Res 74 1998 49 139
20. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 5573 2002 1655 1657
21. F. Tebar, A. Llado, and C. Enrich Role of calmodulin in the modulation of the MAPK signalling pathway and the transactivation of epidermal growth factor receptor mediated by PKC FEBS Lett 517 1-3 2002 206 210
22. A. Giordano, Y.M. Rustum, and C.E. Wenner Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer J Cell Biochem 70 1 1998 1 7
23. J.S. de Jong, P.J. van Diest, P. van der Valk, and J.P. Baak Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis J Pathol 184 1 1998 53 57
24. A. Wells Tumor invasion: role of growth factor-induced cell motility Adv Cancer Res 78 2000 31 101
25. E.M. Gibson, E.S. Henson, N. Haney, J. Villanueva, and S.B. Gibson Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release Cancer Res 62 2 2002 488 496
26. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 3 1995 183 232
27. J.R. Grandis, M.F. Melhem, and W.E. Gooding Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 11 1998 824 832
28. R. Nishikawa, X.D. Ji, and R.C. Harmon A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci USA 91 16 1994 7727 7731
29. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 2-3 1999 241 250
30. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9 S15
31. C.L. Arteaga Epidermal growth factor receptor dependence in human tumors: more than just expression Oncologist 7 Suppl 4 2002 31 39
32. H. Masui, T. Kawamoto, J.D. Sato, B. Wolf, G. Sato, and J. Mendelsohn Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies Cancer Res 44 3 1984 1002 1007
33. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, and G.H. Sato Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 5 1983 511 529
34. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 11 1995 1311 1318
35. Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells J Biol Chem 269 44 1994 27595 27602
36. X. Wu, M. Rubin, and Z. Fan Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody Oncogene 12 7 1996 1397 1403
37. F. Ciardiello, R. Bianco, and V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 9 2000 3739 3747
38. F. Robert, M.P. Ezekiel, and S.A. Spencer Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 13 2001 3234 3243
39. J. Baselga, D. Pfister, and M.R. Cooper Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 4 2000 904 914
40. D.M. Shin, N.J. Donato, and R. Perez-Soler Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 5 2001 1204 1213
41. L. Saltz, M. Rubin, and H. Hochster Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 20 2001 3 (abstr 7)
42. L. Saltz, M. Kies, J. Abbruzzese, N. Azarnia, and M. Needle The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies Proc Am Soc Clin Oncol 22 2003 204 (abstr 817)
43. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 2004 1201 1208
44. D. Cunningham, Y. Humblet, and S. Siena Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 22 2003 252 (abstr 1012)
45. B. Burtness, Y. Li, W. Flood, B. Mattar, and A. Forastiere Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC) Proc Am Soc Clin Oncol 21 2002 226 (abstr 901)
46. Bonner J, Giralt J, Harari P, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 23:LBA, 2004 (abstr 5507).
47. T. Lynch, R. Lilenbaum, and P. Bonomi A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 634 (abstr 7084)
48. R. Rosell, C. Daniel, and R. Ramlau Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 618 (abstr 7012)
49. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 1 2001 17 23
50. D.H. Lynch, and X.D. Yang Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment Semin Oncol 29 1 Suppl 4 2002 47 50
51. R. Figlin, A. Belldegrun, and J. Crawford ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results Proc Am Soc Clin Oncol 21 2002 10 (abstr 35)
52. G. Schwartz, J. Dutcher, and N. Vogelzang Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC) Proc Am Soc Clin Oncol 21 2002 24 (abstr 91)
53. J. Hecht, A. Patnaik, and I. Malik ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis Proc Am Soc Clin Oncol 23 2004 248 (abstr 3511)
54. M. Hambek, C. Solbach, and H.G. Schnuerch Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy Cancer Res 61 3 2001 1045 1049
55. R. Knecht, S. Peters, O. Adunka, K. Strebhardt, W. Gstoettner, and M. Hambek Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents Anticancer Res 23 3 B 2003 2577 2583
56. J. Tabernero, F. Rojo, and E. Jimenez A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors Proc Am Soc Clin Oncol 22 2003 192 (abstr 770)
57. R. Salazar, J. Tabernero, and F. Rojo Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/ pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) Proc Am Soc Clin Oncol 23 2004 127 (abstr 2002)
58. U. Vanhoefer, M. Tewes, and F. Rojo Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol 22 1 2004 175 184
59. T. Trarbach, T. Beyer, and N. Schleucher A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers Proc Am Soc Clin Oncol 23 2004 199 (abstr 3018)
60. A.J.G.K. Barker, and W. Grundy Studies leading to the identification of ZD 1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem 11 2001 1911 1914
61. A.J. Barker, K.H. Gibson, and W. Grundy Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 11 14 2001 1911 1914
62. N.G. Anderson, T. Ahmad, K. Chan, R. Dobson, and N.J. Bundred ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression Int J Cancer 94 6 2001 774 782
63. F. Ciardiello, R. Caputo, and R. Bianco Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin Cancer Res 7 5 2001 1459 1465
64. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, and M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 12 2000 4885 4892
65. J. Baselga, D. Rischin, and M. Ranson Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 21 2002 4292 4302
66. R.S. Herbst, A.M. Maddox, and M.L. Rothenberg Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 18 2002 3815 3825
67. M. Ranson, L.A. Hammond, and D. Ferry ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 9 2002 2240 2250
68. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 5 2004 777 784
69. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 5 2004 785 794
70. E.E. Cohen, F. Rosen, and W.M. Stadler Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 10 2003 1980 1987
71. J.N. Rich, D.A. Reardon, and T. Peery Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 2003
72. M. Moore, E. Winqnquist, and M. Pollak A randomised phase II study of two doses of ZD1839 in patients (pts) with hormone refractory prostate cancer (HRPC): a NCI Canada clinical trials group study Ann Oncol 5 2002 326
73. L. Seymour, G. Goss, and D. Stewart A translational research study of ZD1839 at a dose of 750 mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND Ann Oncol 5 2002 264
74. V.A. Pollack, D.M. Savage, and D.A. Baker Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 2 1999 739 748
75. J.D. Moyer, E.G. Barbacci, and K.K. Iwata Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 21 1997 4838 4848
76. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 13 2001 3267 3279
77. D.F.D. Karp, and T.G. Tensfeldt A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors Lung Cancer 29 Suppl 1 2000 72
78. R. Perez-Soler, A. Chachoua, and M. Huberman A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 20 2001 310 (abstr 1235)
79. N. Finkler, A. Gordon, and M. Crozier Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma Proc Am Soc Clin Oncol 20 2001 208 (abstr 831)
80. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 1 2004 77 85
81. G. Clark, R. Pérez-Soler, L.A. Siu, A. Gordon, and P. Santabárbara Rash severity is predictive of increased survival with erlotinib HCl Proc Am Soc Clin Oncol 2003 196 (abstr 786)
82. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004. J Clin Oncol 22, 14S (July 15 Suppl) (abstr 7010).
83. Herbst R, Prager D, Hermann R, et al. TRIBUTE - a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004. J Clin Oncol 22, 14S (July 15 Suppl) (abstr 7011).
84. M.W. Pedersen, M. Meltorn, L. Damstrup, and H.S. Poulsen The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy Ann Oncol 12 6 2001 745 760
85. M. Hidalgo, C. Erlichman, and E. Rowinsky Phase 1 trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors Proc Am Soc Clin Oncol 21 2002 25 (abstr 65)
86. H. Burris, C. Taylor, and S. Jones A phase I study of GW572016 in patients with solid tumors Proc Am Soc Clin Oncol 22 2003 248 (abstr 994)
87. K. Blackwell, E. Kaplan, and S. Franco A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer Proc Am Soc Clin Oncol 23 2004 (abstr 3006)
88. M. Belanger, C. Jones, C. Germond, and M. Berger A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin Proc Am Soc Clin Oncol 22 2003 244 (abstr 978)
89. C. Erlichman, S.A. Boerner, and C.G. Hallgren The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res 61 2 2001 739 748
90. J. Nemunaitis, I. Eiseman, and C. Cunningham A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors Proc Am Soc Clin Oncol 22 2003 243 (abstr 974)
91. J. Rinehart, G. Wilding, and J. Willson A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI-1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors Proc Am Soc Clin Oncol 22 2003 205 (abstr 821)
92. E. Rowinsky, M. Garrison, and P. Lorusso Administration of CI-1033, an irreversible pan-erbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: a phase I, pharmacokinetic (PK), and food effect study Proc Am Soc Clin Oncol 22 2003 201 (abstr 807)
93. J.G. Christensen, R.E. Schreck, and E. Chan High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo Clin Cancer Res 7 12 2001 4230 4238
94. A.D. Perera, E.V. Kleymenova, and C.L. Walker Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma Clin Cancer Res 6 4 2000 1518 1523
95. S.S. Ng, M.S. Tsao, T. Nicklee, and D.W. Hedley Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 10 2002 777 783
96. B. Li, C.M. Chang, M. Yuan, W.G. McKenna, and H.K. Shu Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas Cancer Res 63 21 2003 7443 7450
97. R. Bianco, I. Shin, and C.A. Ritter Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 18 2003 2812 2822
98. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 1 2002 200 207
99. G. Tortora, R. Caputo, and V. Damiano Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin Cancer Res 9 4 2003 1566 1572
100. A. Viloria-Petit, T. Crombet, and S. Jothy Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 13 2001 5090 5101
101. A.M. Viloria-Petit, and R.S. Kerbel Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies Int J Radiat Oncol Biol Phys 58 3 2004 914 926
102. F. Ciardiello, R. Bianco, and R. Caputo Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2 2004 784 793
103. M.M. Moasser, A. Basso, S.D. Averbuch, and N. Rosen The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 61 19 2001 7184 7188
104. F. Ciardiello, R. Caputo, and R. Bianco Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 5 2000 2053 2563
105. J. Stoehlmacher, J. Brabender, and Y. Shirota Association between mRNA expression level of epidermal growth factor receptor (EGFR), immunohistochemistry (IHC) and response to the EGFR-inhibitor C225 in advanced colorectal carcinoma Proc Am Soc Clin Oncol 20 2001 148 (abstr 593)
106. J. Albanell, F. Rojo, and S. Averbuch Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 1 2002 110 124
107. S.N. Malik, L.L. Siu, and E.K. Rowinsky Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 9 7 2003 2478 2486
108. T.K.W. Doi, and S. Siena Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer Proc Am Soc Clin Oncol 22 2003 258 (abstr 1036)
109. N.Y.Y. Yamamoto, and T. Shimoyama A phase I study of erlotinib HCl in Japanese patients with various types of solid tumors Proc Am Soc Clin Oncol 22 2003 225 (abstr 903)
110. K. Nakagawa, T. Tamura, and S. Negoro Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 6 2003 922 930
111. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2004 2129 2139
112. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 2004 1497 1500
113. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 36 2004 13306 13311
114. V.A. Miller, M.G. Kris, and N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 6 2004 1103 1109
115. K. Albain, S. Green, and P. Ravdin Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814) Proc Am Soc Clin Oncol 21 2002 37 (abstr 143)
116. R.K. Schmidt-Ullrich, R.B. Mikkelsen, and P. Dent Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 10 1997 1191 1197
117. M.T. Sheridan, T. O'Dwyer, C.B. Seymour, and C.E. Mothersill Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Investig 5 4 1997 180 186
118. V. Petersen, W. Weber, M. Schwaiger, and C. Peschel Early prediction of response and overall survival in patients with NSCLC during platinum based chemotherapy with FDG-PET Proc Am Soc Clin Oncol 22 2003 626 (abstr 2517)
119. B. Zee, D. Melnychuk, J. Dancey, and E. Eisenhauer Multinomial phase II cancer trials incorporating response and early progression J Biopharm Stat 9 2 1999 351 363
120. J.A. Kopec, M. Abrahamowicz, and J.M. Esdaile Randomized discontinuation trials: utility and efficiency J Clin Epidemiol 46 9 1993 959 971
121. G.L. Rosner, W. Stadler, and M.J. Ratain Randomized discontinuation design: application to cytostatic antineoplastic agents J Clin Oncol 20 22 2002 4478 4484
122. W.B. Capra Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints Control Clin Trials 25 2 2004 168 177